BChE-Selective Radiologic Agents for Alzheimer's Monitoring
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for monitoring Alzheimer's disease progression and evaluating therapeutic responses lack objective, noninvasive techniques that can accurately assess brain changes before, during, and after treatment, relying heavily on subjective evaluations and imaging agents targeting amyloid plaques or acetylcholinesterase.
Innovation Solution
Development of a class of BChE-selective radiologic agents based on cycloSaligenyl triesters of 2′-deoxy-3′-fluorothymidine, which specifically bind to butyrylcholinesterase (BChE) in the brain, allowing for noninvasive imaging and monitoring of Alzheimer's disease progression and therapeutic responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If subjective evaluation methods are used to monitor Alzheimer's disease progression, then the assessment process is simple, but the measurement precision and objectivity are insufficient
Solution Approach 1:
The patent introduces BChE-selective radiologic agents as intermediary substances that bind specifically to butyrylcholinesterase in the brain. These agents serve as mediators between the imaging system and the disease pathology, enabling objective quantification of BChE levels and plaque burden without requiring complex subjective interpretation. The radiologic agents translate biological information into detectable signals that can be objectively measured and quantified.
2Loss of information
If existing imaging agents targeting amyloid plaques or acetylcholinesterase are used, then the imaging capability is available, but the ability to objectively assess disease progression and therapeutic response is limited
Solution Approach 1:
The patent applies local quality by designing radiologic agents with specific molecular characteristics that enable selective binding to butyrylcholinesterase at particular brain locations where amyloid plaques are present. The agents possess localized affinity properties that concentrate them at disease-relevant sites while maintaining distinguishability from background tissue, allowing precise spatial mapping of BChE distribution and plaque burden.
Solution Approach 2:
The patent utilizes parameter changes by incorporating radioisotopes with specific decay characteristics (positron emission or gamma emission) into the radiologic agents. These radioactive parameters enable the agents to emit detectable signals that can be quantified by imaging systems, transforming the invisible biological information about BChE levels into measurable physical signals that track disease progression and treatment response over time.
3Reliability
If noninvasive imaging methods are developed to monitor brain changes, then the ability to assess disease progression improves, but the complexity of the imaging agents and procedures increases
Solution Approach 1:
The patent achieves universality by designing radiologic agents that simultaneously perform multiple functions: they serve as both the imaging contrast agent and the quantitative marker for BChE levels. The same agent that provides the detectable signal also directly reports on the biological parameter of interest (BChE concentration), eliminating the need for separate measurement systems and reducing overall procedural complexity while maintaining high reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These agents provide a highly efficient means to measure BChE levels, enabling objective assessment of Alzheimer's disease progression and response to therapy, facilitating the development of improved treatment strategies.
Implementation Method 1
cycloSalingenyl pyrimidine nucleoside monophosphates comprising positron emitters or gamma-emitting radiohalides
Data Source
AI summary
Disclosed are certain cycloSalingenyl pyrimidine nucleoside monophosphates comprising positron emitters or gamma-emitting radiohalides, uses thereof for monitoring Alzheimer's disease progression and evaluating response to therapy and process for their preparation.